MedPath

Evaluation of Clinical Efficacy of Tiaoganhuazhuo Decoction Combined with Exercise Therapy on MAFLD Based on Magnetic Resonance Imaging

Phase 1
Conditions
metabolic associated fatty liver disease
Registration Number
ITMCTR2022000065
Lead Sponsor
Guang'anmen Hospital,CHINA ACADEMY OF CHINESE MEDICAL SCIENCE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

? Conform to MAFLD's western medicine diagnostic criteria and TCM syndrome diagnostic criteria;
? Aged between 18 and 65;
? Those who have good compliance, are willing to cooperate with the treatment, and sign the informed consent form.

Exclusion Criteria

? Pregnant or lactating women; ? Complicated with serious diseases of important organs (such as heart, brain, lung and kidney); ? Patients with infectious hepatitis and liver cirrhosis and liver cancer diagnosed by liver biopsy; Or drug-induced liver disease, genetic factors and other specific diseases that can lead to fatty liver; ? Patients with mental and legal disabilities; ? Suspected or actual history of drug abuse; Alcohol consumption history > 5 years, equivalent to alcohol consumption = 40 g /d for men and = 20 g /d for women; Or have a history of heavy drinking within 2 weeks, equivalent to alcohol volume > 80 g /d; ? Those who are known to be allergic to the components of the drug; ? MRI and exercise contraindications; ? Patients who are participating in other drug clinical trials or who have participated in drug clinical trials within the past month.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
MRI-PDFF;
Secondary Outcome Measures
NameTimeMethod
iver function test;the waist;glycosylated hemoglobin;Hypersensitive C-reactive protein;TCM symptom score;Blood lipid test;uric acid;routine blood test;Fasting blood glucose;Body mass index;
© Copyright 2025. All Rights Reserved by MedPath